CN116217745A - 一种藤茶多糖、制备方法及应用 - Google Patents
一种藤茶多糖、制备方法及应用 Download PDFInfo
- Publication number
- CN116217745A CN116217745A CN202211670150.4A CN202211670150A CN116217745A CN 116217745 A CN116217745 A CN 116217745A CN 202211670150 A CN202211670150 A CN 202211670150A CN 116217745 A CN116217745 A CN 116217745A
- Authority
- CN
- China
- Prior art keywords
- polysaccharide
- vine tea
- tea polysaccharide
- agp1
- agp2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 105
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 105
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 241001122767 Theaceae Species 0.000 title claims abstract 17
- 150000004676 glycans Chemical class 0.000 title claims 13
- 101150031810 AGP1 gene Proteins 0.000 claims abstract description 35
- 102100022463 Alpha-1-acid glycoprotein 1 Human genes 0.000 claims abstract description 35
- 101100165241 Arabidopsis thaliana BCP1 gene Proteins 0.000 claims abstract description 35
- 101150110809 ORM1 gene Proteins 0.000 claims abstract description 35
- 102100022460 Alpha-1-acid glycoprotein 2 Human genes 0.000 claims abstract description 34
- 101000678191 Homo sapiens Alpha-1-acid glycoprotein 2 Proteins 0.000 claims abstract description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 21
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims abstract description 16
- 238000004440 column chromatography Methods 0.000 claims abstract description 10
- 230000003544 deproteinization Effects 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 9
- 239000000047 product Substances 0.000 claims abstract description 9
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 claims abstract description 8
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims abstract description 8
- 229940097043 glucuronic acid Drugs 0.000 claims abstract description 8
- 238000001556 precipitation Methods 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 5
- 238000002523 gelfiltration Methods 0.000 claims abstract description 5
- 238000005342 ion exchange Methods 0.000 claims abstract description 5
- 238000003809 water extraction Methods 0.000 claims abstract description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 21
- 239000000243 solution Substances 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000012153 distilled water Substances 0.000 claims description 13
- 239000006228 supernatant Substances 0.000 claims description 12
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 10
- 241001018563 Nekemias grossedentata Species 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 9
- 150000002772 monosaccharides Chemical class 0.000 claims description 9
- 239000002244 precipitate Substances 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 229930182830 galactose Natural products 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 239000012043 crude product Substances 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 5
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 5
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 5
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 5
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 5
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 5
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 5
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 238000000967 suction filtration Methods 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 claims description 3
- 229920005654 Sephadex Polymers 0.000 claims description 3
- 239000012507 Sephadex™ Substances 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 238000002386 leaching Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000004804 polysaccharides Chemical class 0.000 abstract description 92
- 210000002540 macrophage Anatomy 0.000 abstract description 6
- 238000011282 treatment Methods 0.000 abstract description 4
- 238000012916 structural analysis Methods 0.000 abstract description 3
- 229920001284 acidic polysaccharide Polymers 0.000 abstract description 2
- 150000004805 acidic polysaccharides Chemical group 0.000 abstract description 2
- 239000003674 animal food additive Substances 0.000 abstract description 2
- 230000007969 cellular immunity Effects 0.000 abstract description 2
- 238000010612 desalination reaction Methods 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 238000012869 ethanol precipitation Methods 0.000 abstract description 2
- 235000013305 food Nutrition 0.000 abstract description 2
- 230000004957 immunoregulator effect Effects 0.000 abstract description 2
- 244000269722 Thea sinensis Species 0.000 description 54
- 238000010521 absorption reaction Methods 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 238000000862 absorption spectrum Methods 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229940100601 interleukin-6 Drugs 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000005903 acid hydrolysis reaction Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 241000563984 Ampelopsis Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 235000009388 Parthenocissus quinquefolia Nutrition 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000005102 attenuated total reflection Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 230000005934 immune activation Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- UBXYXCRCOKCZIT-UHFFFAOYSA-N biphenyl-3-ol Chemical group OC1=CC=CC(C=2C=CC=CC=2)=C1 UBXYXCRCOKCZIT-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000004192 high performance gel permeation chromatography Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Materials Engineering (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Sustainable Development (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开一种藤茶多糖、制备方法及应用,采取水提醇沉法获得粗多糖,再对粗多糖进行脱蛋白和除盐处理,最后利用离子交换柱层析和凝胶过滤柱层析对粗多糖进行分离纯化,首次制备出两种藤茶多糖纯品(单一多糖),藤茶多糖AGP1和藤茶多糖AGP2,结构分析表明所得藤茶多糖为酸性多糖,富含半乳糖醛酸和葡萄糖醛酸。制备方法温和,完好地保存了多糖分子上的糖链部分,同时制备过程中乙醇比例高且醇沉时间长,多糖得率高;所制备的藤茶多糖AGP1和AGP2具备免疫调节活性,可以显著激活巨噬细胞,诱导细胞免疫因子的表达,可应用于食品、保健品、饲料添加剂及药品等。
Description
技术领域
本发明涉及一种多糖、制备方法及应用,尤其是一种以藤茶为原料提取纯化的藤茶多糖、制备方法及应用。
背景技术
藤茶,学名显齿蛇葡萄(AmpeLopsis grossedentata),系葡萄科(Vitaceae),蛇葡萄属(Ampelopsis)。藤茶全株可入药,具有清热解毒、消炎止痛、止血消肿的功效,民间用其治疗各种皮肤疾病(湿疹、皮炎、牛皮癣等)以及风热感冒带来的各种症状(咽喉肿痛、口舌生疮等),并用于防治糖尿病、高血压、心脏病等疾病。现代药理学表明,藤茶具备降血糖、降血脂、抑菌、抗氧化、抗肿瘤、调节免疫等多种生物学活性。
目前,所报道的藤茶多糖仅限于粗多糖(混合多糖),而非藤茶多糖纯品(单一多糖),即未进行除杂、分离、纯化等步骤,粗多糖含有大量的蛋白分子、色素、无机盐以及其他小分子杂质,产品纯度低,结构复杂且未知等因素严重影响其生物学活性的研究进程。
发明内容
本发明是为了解决现有技术所存在的上述技术问题,提供一种藤茶多糖、制备方法及应用。
本发明的技术解决方案是:一种藤茶多糖AGP1,由→4,6)Gal(1→重复连接构成主链;分子量为5.60×105 Da,糖醛酸含量为40.77%,中性糖含量为42.92%;单糖组成是21.6%的半乳糖醛酸,24.2%的葡萄糖醛酸,31.8%的半乳糖,10.2%阿拉伯糖,7.4%的葡萄糖,3.4%的甘露糖、0.9%的鼠李糖和0.5%的岩藻糖。
一种藤茶多糖AGP2,以→2)Gal(1→和→2,3,4)Glu(1→构成主链;分子量为7.24×105Da,糖醛酸含量为42.59%,中性糖含量为44.37%;单糖组成是33.5%的半乳糖醛酸,26.8%的葡萄糖醛酸,23.3%的半乳糖,6.0%阿拉伯糖,3.3%的葡萄糖,6.2%的甘露糖,0.5%的鼠李糖和0.4%的岩藻糖。
一种上述藤茶多糖的制备方法,其特征在于依次按照如下步骤进行:
a. 原料粉碎:取藤茶茶叶晾晒干燥,粉碎机粉碎至均匀粗粉;
b. 热水提取:取藤茶粗粉,按水料比25:1加入蒸馏水,在95 ℃的水浴锅中热浸提4 h,稍加冷却后过滤并浓缩,得浓缩液;
c. 醇沉:在浓缩液中加入4倍体积的工业乙醇混匀后4℃静置过夜,抽滤,得到一次沉淀;将一次沉淀用少量蒸馏水溶解,再加入等体积工业乙醇4℃静置过夜,抽滤,得到二次沉淀;将二次沉淀冷冻过夜,真空干燥,得到藤茶水溶性粗多糖;
d. 脱蛋白:将藤茶水溶性粗多糖配制成5 mg/ml的水溶液,依次进行四次脱蛋白操作:第一次加入等体积的Sevage试剂(氯仿:正丁醇=4:1),混合震荡20 min,4000 r/min离心5 min,保留上清液;第二至第四次均是在上清液中加入五分之一体积的Sevage试剂,混合震荡20 min,4000 r/min离心5 min,保留上清液;将上清液浓缩后冻干,得到脱蛋白多糖;
e. 离子交换柱层析:DEAE-纤维素用0.5 mol/L的NaCL溶液平衡,依次用蒸馏水、0.10 mol/L、0.30 mol/L、0.50 mol/L的NaCl溶液梯度洗脱,浓缩后透析48 h除盐,冷冻干燥后获得多糖粗品;
f. 凝胶过滤柱层析:Sephadex G-300凝胶色谱柱以蒸馏水洗脱纯化多糖粗品,浓缩冷冻干燥后获得两种多糖纯品,命名为藤茶多糖AGP1和藤茶多糖AGP2。
一种上述的藤茶多糖在制备激活免疫细胞药物中的应用。
本发明是以藤茶为原料,采取水提醇沉法获得粗多糖,再对粗多糖进行脱蛋白和除盐处理,最后利用离子交换柱层析和凝胶过滤柱层析对粗多糖进行分离纯化,首次制备出两种藤茶多糖纯品,藤茶多糖AGP1和藤茶多糖AGP2,结构分析表明所得藤茶多糖为酸性多糖,富含半乳糖醛酸和葡萄糖醛酸。制备方法比较温和,完好地保存了多糖分子上的糖链部分,同时制备过程中乙醇比例高且醇沉时间长,多糖得率高;所制备的藤茶多糖AGP1和AGP2具备免疫调节活性,可以显著激活巨噬细胞,诱导细胞免疫因子的表达,可应用于食品、保健品、饲料添加剂及药品等领域。
附图说明
图1是本发明实施例藤茶多糖AGP1和AGP2的单糖组成与标准品对比图。
图2是本发明实施例藤茶多糖AGP1和AGP2的GC-MS总粒子流图。
图3是本发明实施例藤茶多糖AGP1的紫外吸收光谱图。
图4是本发明实施例藤茶多糖AGP2的紫外吸收光谱图。
图5是本发明实施例藤茶多糖AGP1的红外吸收光谱图。
图6是本发明实施例藤茶多糖AGP2的红外吸收光谱图。
图7是本发明实施例藤茶多糖AGP1的1H核磁共振谱图。
图8是本发明实施例藤茶多糖AGP2的1H核磁共振谱图。
图9是本发明实施例藤茶多糖AGP1和AGP2的对巨噬细胞免疫因子IL-6表达的影响示意图。
具体实施方式
本发明的一种上述藤茶多糖的制备方法,依次按照如下步骤进行:
a. 原料粉碎:取藤茶茶叶晾晒干燥,粉碎机粉碎至均匀粗粉;
b. 热水提取:取藤茶粗粉,按水料比25:1加入蒸馏水,在95℃的水浴锅中热浸提4h,稍加冷却后过滤并浓缩,得浓缩液;
c. 醇沉:在浓缩液中加入4倍体积的工业乙醇混匀后4℃静置过夜,抽滤,得到一次沉淀;将一次沉淀用少量蒸馏水溶解,再加入等体积乙醇4℃静置过夜,抽滤,得到二次沉淀;将二次沉淀冷冻过夜,真空干燥,得到藤茶水溶性粗多糖;粗多糖得率为5.74%;
d. 脱蛋白:将藤茶水溶性粗多糖配制成5 mg/ml的水溶液,依次进行四次脱蛋白操作:第一次加入等体积的Sevage试剂(氯仿:正丁醇=4:1),混合震荡20 min,4000 r/min离心5 min,保留上清液;第二至第四次均是在上清液中加入五分之一体积的Sevage试剂,混合震荡20 min,4000 r/min离心5 min,保留上清液;四次脱蛋白处理后,将上清液浓缩后冷冻干燥,得到脱蛋白多糖;
e. 离子交换柱层析:DEAE-纤维素用0.5 mol/L的NaCL溶液平衡,依次用蒸馏水、0.10 mol/L、0.30 mol/L、0.50 mol/L的NaCl溶液梯度洗脱,浓缩后透析48 h除盐,冷冻干燥后获得多糖粗品;
f. 凝胶过滤柱层析:Sephadex G-300凝胶色谱柱以蒸馏水洗脱纯化多糖粗品,浓缩冷冻干燥后获得两种多糖纯品,命名为藤茶多糖AGP1和藤茶多糖AGP2,纯化得率分别为36.2%和41.5%。
实验:
一、本发明实施例藤茶多糖AGP1和AGP2的理化性质测定
对所得两种多糖的理化性质分别进行测定,所得理化指标如表1所示:
表1 藤茶多糖的理化指标
结构分析表明所得藤茶多糖为酸性多糖,富含半乳糖醛酸和葡萄糖醛酸。
多糖纯度及分子量测定采用高效凝胶渗透色谱法,糖含量测定采用苯酚硫酸法,蛋白含量测定采用考马斯亮蓝法,糖醛酸含量测定采用间羟联苯法。
二. 本发明实施例藤茶多糖AGP1和AGP2的单糖组成测定及连接方式分析
分别将所得到的藤茶多糖AGP1和藤茶多糖AGP2为样品,按照下述方法处理:
(1)酸水解:样品中加入三氟乙酸,110 ℃反应2 h后,加少量甲醇洗涤,70 ℃蒸干反应液,重复洗涤操作3-5次;溶解于少量蒸馏水中,得到多糖酸水解产物;
(2)单糖组成测定:采用高效阴离子交换色谱法兼备脉冲安倍检测器,测定两种组分的单糖组成如图1所示。图1中各峰的序号对应为1.岩藻糖 2.阿拉伯糖 3.鼠李糖 4.半乳糖 5.葡萄糖 6.甘露糖 7.半乳糖醛酸 8.葡萄糖醛酸。
与标准品比对得到测定结果如表2所示:
表2 藤茶多糖的单糖组成
(3)多糖连接方式分析:对多糖进行酸水解和甲基化,并对结果进行GC-MS分析(图2),分析得到AGP1和AGP2的主链连接方式分别如表3、表4所示:藤茶多糖AGP1由→4,6)Gal(1→重复连接构成主链;藤茶多糖AGP2以→2)Gal(1→和→2,3,4)Glu(1→构成主链。
表3 AGP1的甲基化分析结果
表4 AGP2的甲基化分析结果
三. 本发明实施例藤茶多糖AGP1和AGP2的光谱分析
分别将所得到的藤茶多糖AGP1和藤茶多糖AGP2为样品,将样品配制为1.0 mg/mL的水溶液,于200 nm至800 nm波长范围内进行紫外扫描;采用衰减全反射光谱(ATR)对样品进行红外光谱扫描。
藤茶多糖AGP1和AGP2的紫外吸收光谱图如图3、图4所示。由于蛋白质在280 nm处有特征吸收,糖类物质在200 nm附近有特征吸收,因此可以通过紫外扫描初步判定糖类和蛋白质的存在。紫外扫描显示,在200 nm左右有强烈吸收,而在280 nm处有较弱吸收,说明AGP1和AGP2为糖蛋白复合物。
AGP1的红外吸收光谱如图5所示,AGP1在3286 cm-1处存在强且宽的峰,是-OH的伸缩振动峰;在2936 cm-1处存在吸收,这表示组分中存在糖类特征峰,是糖类-CH2 或-CH3的伸缩振动峰;1745 cm-1附近检测到糖醛酸的吸收峰;1599 cm-1附近检测到C=O的伸缩振动峰;1424 cm-1处为C-H的变角振动峰;1025 cm-1附近检测到C-O-C或C-O伸缩振动。
AGP2的红外吸收光谱图如图6所示,AGP2在3304 cm-1附近有强吸收,是-OH的伸缩振动峰;2924 cm-1附近检测到-CH2 或-CH3的伸缩振动峰;1746 cm-1附近检测到糖醛酸的吸收峰;1597 cm-1附近检测到C=O的伸缩振动峰;1418 cm-1处为C-H的变角振动;1024 cm-1附近检测到C-O-C和C-O伸缩振动。
四. 本发明实施例藤茶多糖AGP1和AGP2的核磁氢谱分析
称取20 mg藤茶多糖AGP1和AGP2,分别溶于1 ml D2O中,用移液枪转移至核磁管中,通过NMR光谱仪对样品进行测定。
如图7所示,AGP1的信号集中在δH3.2-5.2 ppm之间,δH4.70 ppm处为溶剂峰,δH3.2-4.2 ppm为环质子信号,本氢谱中显示AGP1异头碳上氢的化学位移为δH5.13 ppm,表示该多糖含有一类端基质子,为α构型的半乳糖的异头氢信号。
如图8所示,AGP2的信号集中在δH3.2-5.2 ppm之间,δH4.71 ppm处为溶剂峰,δH3.2-4.4 ppm为环质子信号,本氢谱中显示AGP2异头碳上氢的化学位移为δH5.13 ppm和δH5.26 ppm,表示该多糖含有两类端基质子,为α构型的半乳糖和葡萄糖的的异头氢信号。
位于δH3.2-4.4 ppm处的共振峰代表了糖环上其他氢原子的化学位移。δH1-3.2ppm之间为蛋白质的氨基酸残基上氢的化学位移信号,表明多糖中含有微量的蛋白质。
五. 分别以所得到的藤茶多糖AGP1和藤茶多糖AGP2为样品,测定藤茶多糖的免疫刺激活性
(1)巨噬细胞培养:RAW264.7巨噬细胞株培养于RPMI 1640培养基中,培养基中预先加入了10%的胎牛血清、100 U/ml青霉素和100 U/ml硫酸链霉素,经0.22 μm滤膜过滤后使用;细胞在37℃,5% CO2的孵箱中孵育,三天传一代。
(2)测定细胞因子:将培养的巨噬细胞分为以下处理组:空白对照0 μg/mL、样品10μg/mL、样品50 μg/mL、样品100 μg/mL。孵育24 h后,收集细胞和培养液,采用ELISA方法测定白细胞介素6(IL-6)的含量,结果如图9所示。
结果表明:藤茶多糖AGP1和AGP2可以明显促进IL-6的表达,100 μg/mL达到最大值,分别为空白对照组的7.9倍和6.1倍,AGP1的免疫激活效果更好,提示两种藤茶多糖AGP1和AGP2具有良好的免疫激活作用。
Claims (4)
1.一种藤茶多糖AGP1,其特征在于:由→4,6)Gal(1→重复连接构成主链;分子量为5.60×105 Da,糖醛酸含量为40.77%,中性糖含量为42.92%;单糖组成是21.6%的半乳糖醛酸,24.2%的葡萄糖醛酸,31.8%的半乳糖,10.2%阿拉伯糖,7.4%的葡萄糖,3.4%的甘露糖、0.9%的鼠李糖和0.5%的岩藻糖。
2.一种藤茶多糖AGP2,其特征在于:以→2)Gal(1→和→2,3,4)Glu(1→构成主链;分子量为7.24×105Da,糖醛酸含量为42.59%,中性糖含量为44.37%;单糖组成是33.5%的半乳糖醛酸,26.8%的葡萄糖醛酸,23.3%的半乳糖,6.0%阿拉伯糖,3.3%的葡萄糖,6.2%的甘露糖,0.5%的鼠李糖和0.4%的岩藻糖。
3.一种如权利要求1或2所述藤茶多糖的制备方法,其特征在于依次按照如下步骤进行:
a. 原料粉碎:取藤茶茶叶晾晒干燥,粉碎机粉碎至均匀粗粉;
b. 热水提取:取藤茶粗粉,按水料比25:1加入蒸馏水,在95 ℃的水浴锅中热浸提4 h,稍加冷却后过滤并浓缩,得浓缩液;
c. 醇沉:在浓缩液中加入4倍体积的工业乙醇混匀后静置过夜,抽滤,得到一次沉淀;将一次沉淀用少量蒸馏水溶解,再加入等体积的工业乙醇静置过夜,抽滤,得到二次沉淀;将二次沉淀冷冻过夜,真空干燥,得到藤茶水溶性粗多糖;
d. 脱蛋白:将藤茶水溶性粗多糖配制成5 mg/ml的水溶液,依次进行四次脱蛋白操作:第一次加入等体积的Sevage试剂(氯仿:正丁醇=4:1),混合震荡20 min,4000 r/min离心5min,保留上清液;第二至第四次均是在上清液中加入五分之一体积的Sevage试剂,混合震荡20 min,4000 r/min离心5 min,保留上清液;将上清液浓缩后冻干,得到脱蛋白多糖;
e. 离子交换柱层析:DEAE-纤维素用0.5 mol/L的NaCL溶液平衡,依次用蒸馏水、0.10mol/L、0.30 mol/L、0.50 mol/L的NaCl溶液梯度洗脱,浓缩后透析48 h除盐,冷冻干燥后获得多糖粗品;
f. 凝胶过滤柱层析:Sephadex G-300凝胶色谱柱以蒸馏水洗脱纯化多糖粗品,浓缩冷冻干燥后获得两种多糖纯品,命名为藤茶多糖AGP1和藤茶多糖AGP2。
4.一种如权利要求1或权利要求2所述的藤茶多糖在制备激活免疫细胞药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211670150.4A CN116217745B (zh) | 2022-12-23 | 2022-12-23 | 一种藤茶多糖、制备方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211670150.4A CN116217745B (zh) | 2022-12-23 | 2022-12-23 | 一种藤茶多糖、制备方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116217745A true CN116217745A (zh) | 2023-06-06 |
CN116217745B CN116217745B (zh) | 2024-04-26 |
Family
ID=86572161
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211670150.4A Active CN116217745B (zh) | 2022-12-23 | 2022-12-23 | 一种藤茶多糖、制备方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116217745B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116425901A (zh) * | 2023-06-13 | 2023-07-14 | 西南民族大学 | 苦笋多糖及其制备方法和用途 |
CN116655820A (zh) * | 2023-06-07 | 2023-08-29 | 科乐美(广州)生物科技有限公司 | 一种藤茶酸性多糖AGP-3a及其提取分离方法和在制备抗炎化妆品中的用途 |
CN116731217A (zh) * | 2023-06-07 | 2023-09-12 | 科乐美(广州)生物科技有限公司 | 一种藤茶酸性多糖AGP-2a及其制备方法和在制备抗炎化妆品中的用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101973976A (zh) * | 2010-09-16 | 2011-02-16 | 湖北民族学院 | 从藤茶中提取二氢杨梅素、藤茶多糖和藤茶多酚的方法 |
CN105732830A (zh) * | 2014-12-08 | 2016-07-06 | 郑州国手生物科技有限公司 | 藤茶水溶性多糖的提取工艺 |
CN108070039A (zh) * | 2017-12-27 | 2018-05-25 | 张家界茅岩莓有限公司 | 一种从显齿蛇葡萄中同步提取多糖和黄酮的方法 |
CN112457421A (zh) * | 2020-11-16 | 2021-03-09 | 周恩正 | 二氢杨梅素和多糖的提取分离方法 |
-
2022
- 2022-12-23 CN CN202211670150.4A patent/CN116217745B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101973976A (zh) * | 2010-09-16 | 2011-02-16 | 湖北民族学院 | 从藤茶中提取二氢杨梅素、藤茶多糖和藤茶多酚的方法 |
CN105732830A (zh) * | 2014-12-08 | 2016-07-06 | 郑州国手生物科技有限公司 | 藤茶水溶性多糖的提取工艺 |
CN108070039A (zh) * | 2017-12-27 | 2018-05-25 | 张家界茅岩莓有限公司 | 一种从显齿蛇葡萄中同步提取多糖和黄酮的方法 |
CN112457421A (zh) * | 2020-11-16 | 2021-03-09 | 周恩正 | 二氢杨梅素和多糖的提取分离方法 |
Non-Patent Citations (4)
Title |
---|
LIU CY等: "Effect of steam explosion pretreatment on the structure and bioactivity of Ampelopsis grossedentata polysaccharides", INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, vol. 185, pages 194 - 205, XP086714344, DOI: 10.1016/j.ijbiomac.2021.06.002 * |
罗祖友 等: "藤茶水溶性多糖的分离纯化及性质的研究", 食品科学, no. 01, pages 129 - 132 * |
罗祖友;陈根洪;郑小江;吴谋成;: "藤茶多糖AGP-3的分离纯化与结构的初步鉴定", 时珍国医国药, no. 07, pages 147 - 149 * |
罗祖友;陈根洪;陈业;吴谋成;: "藤茶多糖抗肿瘤及免疫调节作用的研究", 食品科学, no. 08, pages 457 - 461 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116655820A (zh) * | 2023-06-07 | 2023-08-29 | 科乐美(广州)生物科技有限公司 | 一种藤茶酸性多糖AGP-3a及其提取分离方法和在制备抗炎化妆品中的用途 |
CN116731217A (zh) * | 2023-06-07 | 2023-09-12 | 科乐美(广州)生物科技有限公司 | 一种藤茶酸性多糖AGP-2a及其制备方法和在制备抗炎化妆品中的用途 |
CN116655820B (zh) * | 2023-06-07 | 2024-05-14 | 科乐美(广州)生物科技有限公司 | 一种藤茶酸性多糖AGP-3a及其提取分离方法和在制备抗炎化妆品中的用途 |
CN116731217B (zh) * | 2023-06-07 | 2024-06-04 | 科乐美(广州)生物科技有限公司 | 一种藤茶酸性多糖AGP-2a及其制备方法和在制备抗炎化妆品中的用途 |
CN116425901A (zh) * | 2023-06-13 | 2023-07-14 | 西南民族大学 | 苦笋多糖及其制备方法和用途 |
CN116425901B (zh) * | 2023-06-13 | 2023-08-18 | 西南民族大学 | 苦笋多糖及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN116217745B (zh) | 2024-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN116217745B (zh) | 一种藤茶多糖、制备方法及应用 | |
Meng et al. | Structural characterization and immunomodulating activities of polysaccharides from a newly collected wild Morchella sextelata | |
US10835552B2 (en) | Method for preparing linseed polysaccharide having antiviral activity and immunological activity, and use of the linseed polysaccharide | |
CN110256593B (zh) | 一种大球盖菇多糖及其制备方法和应用 | |
CN114591448B (zh) | 一种桑树桑黄子实体甘露半乳聚糖及其制备和用途 | |
CN110128562A (zh) | 一种抗肿瘤补骨脂多糖及其提取分离方法和在制备抗肿瘤药物方面的应用 | |
CN110540603B (zh) | 知母多糖及其制备方法、鉴定方法和应用 | |
CN112358553B (zh) | 一种多糖sm-0.2m及其制备的抗肿瘤产品 | |
CN112062866B (zh) | 一种猴头菌富硒多糖及其制备方法和用途 | |
CN110862463A (zh) | 具有生物活性的紫花苜蓿根部多糖及其硒化改性多糖的制备 | |
CN111320708B (zh) | 一种芦根多糖及其制备方法和用途 | |
CN112794925B (zh) | 一种阳春砂多糖及其制备方法和应用 | |
CN114989323A (zh) | 具有抗肿瘤活性的杜仲叶多糖、提取分离方法和在制备抗肿瘤药物的补充剂中的应用 | |
CN116655820B (zh) | 一种藤茶酸性多糖AGP-3a及其提取分离方法和在制备抗炎化妆品中的用途 | |
CN113717296A (zh) | 一种杜仲酸性多糖、提取方法及其在制备抗结肠癌药物中的应用 | |
CN116731217B (zh) | 一种藤茶酸性多糖AGP-2a及其制备方法和在制备抗炎化妆品中的用途 | |
CN116120475B (zh) | 一种云莓均一多糖rcp-90-1及其分离纯化方法和作为抗肿瘤药物的应用 | |
CN110894244B (zh) | 一种土鳖虫多糖的结构及其用途 | |
CN115043956B (zh) | 一种接骨木多糖及其多糖组合物与应用 | |
CN115651089B (zh) | 一种具有抗氧化活性的天麻多糖 | |
CN115558035B (zh) | 一种具有免疫调节活性的天麻多糖 | |
CN115232225B (zh) | 一种熟地黄均一多糖及其制备方法和应用 | |
CN113637089B (zh) | 一种醇水两溶性党参葡果聚糖、制备工艺及抗肿瘤应用 | |
CN110483653B (zh) | 一种具有免疫活性的香菇多糖组分的制备方法及产品和应用 | |
CN116425894A (zh) | 一种中分子量铁皮石斛多糖及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |